share_log

荃信生物-B:自願公告QX005N結節性癢疹III期臨床試驗順利達成首例受試者入組

QYUNS-B: VOLUNTARY ANNOUNCEMENTFIRST SUBJECT ENROLLMENT FORQX005N PHASE III CLINICAL TRIAL FOR THE TREATMENT OF PRURIGONODULARIS

Hong Kong Stock Exchange ·  May 29 18:49

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.